"Ultragenyx doses first subject in study of GTX-102 for angelman syndrome" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the efficacy and safety of GTX-102 (apazunersen), an ...

Amnesty International calls on the Salvadoran authorities to immediately and unconditionally guarantee the release of ...

EXCLUSIVE: Newly public Angel Studios has partnered with 2521 Entertainment to acquire 100% of the David animated film and TV franchise from Slingshot USA. The partners are forking out $78 million for ...

As ChatGPT writing floods LinkedIn, people are taking extra time to make sure their writing sounds like a human.

BIG TIMBER, Mont. – Governor Greg Gianforte recently visited Sweet Grass County as part of his 56 County Tour to discuss the Angel Initiative, a program aimed at assisting Montanans with substance use ...

Fresh off its IPO, the indie disruptor is betting big on global audiences. But its values-based playbook may not translate everywhere. By Scott Roxborough Europe Bureau Chief Angel’s secret weapon has ...

MIDDLETON, Mass., Sept. 22, 2025 /PRNewswire/ -- MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today ...

It's no secret that NBA legend Shaquille O'Neal has been a mentor for Chicago Sky superstar Angel Reese ever since Reese was playing for the LSU Tigers (which is also Shaq's alma mater). Since then, ...

The epidemiology of tumor lysis syndrome is evolving with the introduction of newer therapies. The occurrence of tumor lysis syndrome has become a less predictable but increasingly important aspect of ...